Adial Pharmaceuticals, Inc.
ADILNASDAQHealthcareBiotechnology
Previous close
$6.215
+$0.315 · +5.34%
ADIL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
33
Weakening
Sentiment
73
Bullish
Risk resilience
28
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAdial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Cary John Claiborne
- Listed since
- Jul 27, 2018
- Employees
- 5
Market position
Day range
Current $6.215
52-week range
Current $6.215
- Open
- $5.95
- Previous close
- $5.90
- Volume
- 81.99K
- 0.24× average
- Average volume
- 346.3K
- Average daily volume
- Market cap
- 5.96M USD
- Beta
- 1.43
- Market reference 1
- 50-day average
- $3.349
- +85.58% above average
- 200-day average
- $3.8229
- +62.57% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -2.2M USD
- EV / EBITDA
- 0.28×
- Earnings yield
- -216.92%
- Free cash flow yield
- -176.55%
Profitability & efficiency
- Return on equity
- -151.18%
- Return on assets
- -117.34%
- Return on invested capital
- -144.40%
Financial health
- Current ratio
- 4.42×
- Altman Z-score
- -12.38
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 564 USD | — | — |
| Gross profit | — | — | −564 USD | — | — |
| Research and development | 2.62M USD | 3.23M USD | 1.27M USD | 1.95M USD | 8.4M USD |
| Selling, general, and administrative | 5.18M USD | 5.06M USD | 5.62M USD | 8.91M USD | 9.34M USD |
| Operating expenses | 7.8M USD | 8.28M USD | 6.89M USD | 10.86M USD | 19.29M USD |
| Interest income | 149.57K USD | 178.66K USD | 69.78K USD | 63.34K USD | 6.54K USD |
| Depreciation and amortization | 565 USD | 565 USD | 564 USD | 564 USD | 55.11K USD |
| Operating income | −7.8M USD | −8.28M USD | −6.89M USD | −10.86M USD | −19.29M USD |
| Net income | −7.98M USD | −13.2M USD | −7M USD | −12.73M USD | −19.42M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
ADIL news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 6, 2026 | 1:25 | — | — |
Stock split | Aug 7, 2023 | 1:25 | — | — |
Effective Feb 6, 2026
1:25
Effective Aug 7, 2023
1:25
ADIL peers
ETFs holding ADIL
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research ADILresearch.disclaimer